Cargando…

A DNA Vaccine Encoding the Full-Length Spike Protein of Beta Variant (B.1.351) Elicited Broader Cross-Reactive Immune Responses against Other SARS-CoV-2 Variants

The SARS-CoV-2 pandemic remains an ongoing threat to global health with emerging variants, especially the Omicron variant and its sub-lineages. Although large-scale vaccination worldwide has delivered outstanding achievements for COVID-19 prevention, a declining effectiveness to a different extent i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Gan, Zhang, Zhiyu, Ding, Yuan, Hou, Jiawang, Liu, Ying, Zhang, Mengying, Sui, Cheng, Wang, Limei, Xu, Xin, Gao, Xiaoming, Kou, Zhihua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054764/ https://www.ncbi.nlm.nih.gov/pubmed/36992097 http://dx.doi.org/10.3390/vaccines11030513

Ejemplares similares

COVID-19 rise in Bangladesh correlates with increasing detection of B.1.351 variant
por: Saha, Senjuti, et al.
Publicado: (2021)

Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice
por: Martinez, David R., et al.
Publicado: (2021)

Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice
por: Martinez, David R., et al.
Publicado: (2021)

The SARS-CoV-2 B.1.351 Variant Can Transmit in Rats But Not in Mice
por: Zhang, Cheng, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351
por: Shen, Xiaoying, et al.
Publicado: (2021)

Detection of B.1.351 SARS-CoV-2 Variant Strain — Zambia, December 2020
por: Mwenda, Mulenga, et al.
Publicado: (2021)

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant
por: Shinde, Vivek, et al.
Publicado: (2021)

The Infection and Pathogenicity of SARS-CoV-2 Variant B.1.351 in hACE2 Mice
por: Chen, Qi, et al.
Publicado: (2021)

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
por: Wang, Pengfei, et al.
Publicado: (2021)

SARS-CoV-2 B.1.1.7 and B.1.351 Spike variants bind human ACE2 with increased affinity
por: Ramanathan, Muthukumar, et al.
Publicado: (2021)

SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity
por: Ramanathan, Muthukumar, et al.
Publicado: (2021)

Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant
por: Edara, Venkata Viswanadh, et al.
Publicado: (2021)

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
por: Hoffmann, Markus, et al.
Publicado: (2021)

Linked Clusters of SARS-CoV-2 Variant B.1.351 — Maryland, January–February 2021
por: Feder, Kenneth A., et al.
Publicado: (2021)

Infection with the SARS-CoV-2 B.1.351 variant is lethal in aged BALB/c mice
por: Yasui, Fumihiko, et al.
Publicado: (2022)

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
por: Zhou, Daming, et al.
Publicado: (2021)

Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization
por: Wang, Pengfei, et al.
Publicado: (2021)

Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants
por: Du, Shuo, et al.
Publicado: (2021)

Functional Effects of Receptor-Binding Domain Mutations of SARS-CoV-2 B.1.351 and P.1 Variants
por: Bayarri-Olmos, Rafael, et al.
Publicado: (2021)

SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2021)

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
por: Madhi, Shabir A., et al.
Publicado: (2021)

Linked transmission chains of imported SARS-CoV-2 variant B.1.351 across mainland France, January 2021
por: Calba, Clémentine, et al.
Publicado: (2021)

Case series of four re-infections with a SARS-CoV-2 B.1.351 variant, Luxembourg, February 2021
por: Staub, Thérèse, et al.
Publicado: (2021)

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
por: Abu-Raddad, Laith J., et al.
Publicado: (2021)

Descriptive epidemiology of SARS‐CoV‐2 Beta (B.1.351) variant cases in England, December 2020 to June 2022
por: Sinnathamby, Mary A., et al.
Publicado: (2023)

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2021)

Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques
por: Munster, Vincent J., et al.
Publicado: (2021)

Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques
por: Munster, Vincent J., et al.
Publicado: (2021)

COVID vaccine efficacy against the B.1.351 (“South African”) variant—The urgent need to lay the groundwork for possible future challenge studies
por: Eyal, Nir, et al.
Publicado: (2021)

Infection of wild-type mice by SARS-CoV-2 B.1.351 variant indicates a possible novel cross-species transmission route
por: Pan, Ting, et al.
Publicado: (2021)

SARS-CoV-2 antibodies specific to the mesa and inner side of spike protein receptor binding domain maintain high affinities for both D614G and b.1.351 variants
por: Li, Kan, et al.
Publicado: (2022)

A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters
por: Wuertz, Kathryn McGuckin, et al.
Publicado: (2021)

Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines
por: Yang, Yong, et al.
Publicado: (2021)

Introduction of SARS-CoV-2 variant of concern 20h/501Y.V2 (B.1.351) from Malawi to Italy
por: Novazzi, Federica, et al.
Publicado: (2021)

Vaccine breakthrough infection and onward transmission of SARS-CoV-2 Beta (B.1.351) variant, Bavaria, Germany, February to March 2021
por: Kroidl, Inge, et al.
Publicado: (2021)

Impact of BNT162b first vaccination on the immune transcriptome of elderly patients infected with the B.1.351 SARS-CoV-2 variant
por: Knabl, Ludwig, et al.
Publicado: (2021)

Impact of BNT162b First Vaccination on the Immune Transcriptome of Elderly Patients Infected with the B.1.351 SARS-CoV-2 Variant
por: Knabl, Ludwig, et al.
Publicado: (2021)

B.1.351 SARS-CoV-2 Variant Exhibits Higher Virulence but Less Viral Shedding than That of the Ancestral Strain in Young Nonhuman Primates
por: Bai, Yu, et al.
Publicado: (2022)

Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant
por: Yinda, Claude Kwe, et al.
Publicado: (2021)

Four COVID-19 Cases of New Variant B.1.351 First Emerging in South Africa in Chinese Passengers on Same Flight — Shenzhen, China, January 2021
por: Cheng, Cong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_esva4s2svaplc83ile7vi91oen